Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer

A retrospective cohort study

Elena Verzoni, Ugo de Giorgi, Lisa Derosa, Orazio Caffo, Francesco Boccardo, Gaetano Facchini, Luca Porcu, Fabio de Vincenzo, Alberto Zaniboni, Vincenzo Emanuele Chiuri, Lucia Fratino, Daniele Santini, Vincenzo Adamo, Rocco de Vivo, Angelo Dinota, Caterina Messina, Riccardo Ricotta, Claudia Caserta, Claudio Scavelli, Marina Susi & 7 others Alfredo Tartarone, Giuseppe Surace, Alessandra Mosca, Michele Bruno, Sandro Barni, Paolo Grassi, Giuseppe Procopio

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We aimed to identify clinical predictors of long-term response to abiraterone (defined as >12 months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 Italian centers. The Cox proportional hazards model was used to analyze the association between clinical features and the duration of drug exposure. Results were expressed as hazard ratios (HR) with associated 95% confidence intervals (CI). A total of 143 patients met the inclusion criteria. Their median age was 73 years, median Gleason score 8 and median abiraterone exposure 20 months. At the univariate analysis, a significant correlation with the duration of abiraterone exposure was found for Gleason score (HR 0.82, 95% CI 0.71-0.96; p=0.012), PSA (HR 1.10, 95% CI 1.03-1.18; p=0.08) and lactic dehydrogenase levels (HR 1.22, 95% CI 1.02-1.46; p=0.027), while the association between lower alkaline phosphatase levels and treatment duration was marginally significant (HR 1.07, 95% CI 0.99-1.16; p=0.074). Only PSA and Gleason score were predictive of long-term treatment duration in the multivariate analysis. No other clinical factors resulted to be predictive of sustained response to abiraterone, including metastatic disease at diagnosis and visceral disease, suggesting that all subgroups of patients may derive a substantial clinical benefit from abiraterone treatment. These findings need to be validated in prospective, larger studies.

Original languageEnglish
Pages (from-to)40085-40094
Number of pages10
JournalOncotarget
Volume7
Issue number26
Publication statusPublished - 2016

Fingerprint

Castration
Prostatic Neoplasms
Cohort Studies
Retrospective Studies
Confidence Intervals
Neoplasm Grading
docetaxel
Proportional Hazards Models
Pharmaceutical Preparations
Alkaline Phosphatase
Oxidoreductases
Milk
Therapeutics
Multivariate Analysis
abiraterone
Prospective Studies

Keywords

  • Abiraterone acetate
  • Castration-resistant
  • Predictive factors
  • Prostate cancer
  • Retrospective studies

ASJC Scopus subject areas

  • Oncology

Cite this

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer : A retrospective cohort study. / Verzoni, Elena; de Giorgi, Ugo; Derosa, Lisa; Caffo, Orazio; Boccardo, Francesco; Facchini, Gaetano; Porcu, Luca; de Vincenzo, Fabio; Zaniboni, Alberto; Chiuri, Vincenzo Emanuele; Fratino, Lucia; Santini, Daniele; Adamo, Vincenzo; de Vivo, Rocco; Dinota, Angelo; Messina, Caterina; Ricotta, Riccardo; Caserta, Claudia; Scavelli, Claudio; Susi, Marina; Tartarone, Alfredo; Surace, Giuseppe; Mosca, Alessandra; Bruno, Michele; Barni, Sandro; Grassi, Paolo; Procopio, Giuseppe.

In: Oncotarget, Vol. 7, No. 26, 2016, p. 40085-40094.

Research output: Contribution to journalArticle

Verzoni, E, de Giorgi, U, Derosa, L, Caffo, O, Boccardo, F, Facchini, G, Porcu, L, de Vincenzo, F, Zaniboni, A, Chiuri, VE, Fratino, L, Santini, D, Adamo, V, de Vivo, R, Dinota, A, Messina, C, Ricotta, R, Caserta, C, Scavelli, C, Susi, M, Tartarone, A, Surace, G, Mosca, A, Bruno, M, Barni, S, Grassi, P & Procopio, G 2016, 'Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: A retrospective cohort study', Oncotarget, vol. 7, no. 26, pp. 40085-40094.
Verzoni, Elena ; de Giorgi, Ugo ; Derosa, Lisa ; Caffo, Orazio ; Boccardo, Francesco ; Facchini, Gaetano ; Porcu, Luca ; de Vincenzo, Fabio ; Zaniboni, Alberto ; Chiuri, Vincenzo Emanuele ; Fratino, Lucia ; Santini, Daniele ; Adamo, Vincenzo ; de Vivo, Rocco ; Dinota, Angelo ; Messina, Caterina ; Ricotta, Riccardo ; Caserta, Claudia ; Scavelli, Claudio ; Susi, Marina ; Tartarone, Alfredo ; Surace, Giuseppe ; Mosca, Alessandra ; Bruno, Michele ; Barni, Sandro ; Grassi, Paolo ; Procopio, Giuseppe. / Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer : A retrospective cohort study. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 40085-40094.
@article{5629de2f84ea492b89563de98616d500,
title = "Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: A retrospective cohort study",
abstract = "We aimed to identify clinical predictors of long-term response to abiraterone (defined as >12 months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 Italian centers. The Cox proportional hazards model was used to analyze the association between clinical features and the duration of drug exposure. Results were expressed as hazard ratios (HR) with associated 95{\%} confidence intervals (CI). A total of 143 patients met the inclusion criteria. Their median age was 73 years, median Gleason score 8 and median abiraterone exposure 20 months. At the univariate analysis, a significant correlation with the duration of abiraterone exposure was found for Gleason score (HR 0.82, 95{\%} CI 0.71-0.96; p=0.012), PSA (HR 1.10, 95{\%} CI 1.03-1.18; p=0.08) and lactic dehydrogenase levels (HR 1.22, 95{\%} CI 1.02-1.46; p=0.027), while the association between lower alkaline phosphatase levels and treatment duration was marginally significant (HR 1.07, 95{\%} CI 0.99-1.16; p=0.074). Only PSA and Gleason score were predictive of long-term treatment duration in the multivariate analysis. No other clinical factors resulted to be predictive of sustained response to abiraterone, including metastatic disease at diagnosis and visceral disease, suggesting that all subgroups of patients may derive a substantial clinical benefit from abiraterone treatment. These findings need to be validated in prospective, larger studies.",
keywords = "Abiraterone acetate, Castration-resistant, Predictive factors, Prostate cancer, Retrospective studies",
author = "Elena Verzoni and {de Giorgi}, Ugo and Lisa Derosa and Orazio Caffo and Francesco Boccardo and Gaetano Facchini and Luca Porcu and {de Vincenzo}, Fabio and Alberto Zaniboni and Chiuri, {Vincenzo Emanuele} and Lucia Fratino and Daniele Santini and Vincenzo Adamo and {de Vivo}, Rocco and Angelo Dinota and Caterina Messina and Riccardo Ricotta and Claudia Caserta and Claudio Scavelli and Marina Susi and Alfredo Tartarone and Giuseppe Surace and Alessandra Mosca and Michele Bruno and Sandro Barni and Paolo Grassi and Giuseppe Procopio",
year = "2016",
language = "English",
volume = "7",
pages = "40085--40094",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "26",

}

TY - JOUR

T1 - Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer

T2 - A retrospective cohort study

AU - Verzoni, Elena

AU - de Giorgi, Ugo

AU - Derosa, Lisa

AU - Caffo, Orazio

AU - Boccardo, Francesco

AU - Facchini, Gaetano

AU - Porcu, Luca

AU - de Vincenzo, Fabio

AU - Zaniboni, Alberto

AU - Chiuri, Vincenzo Emanuele

AU - Fratino, Lucia

AU - Santini, Daniele

AU - Adamo, Vincenzo

AU - de Vivo, Rocco

AU - Dinota, Angelo

AU - Messina, Caterina

AU - Ricotta, Riccardo

AU - Caserta, Claudia

AU - Scavelli, Claudio

AU - Susi, Marina

AU - Tartarone, Alfredo

AU - Surace, Giuseppe

AU - Mosca, Alessandra

AU - Bruno, Michele

AU - Barni, Sandro

AU - Grassi, Paolo

AU - Procopio, Giuseppe

PY - 2016

Y1 - 2016

N2 - We aimed to identify clinical predictors of long-term response to abiraterone (defined as >12 months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 Italian centers. The Cox proportional hazards model was used to analyze the association between clinical features and the duration of drug exposure. Results were expressed as hazard ratios (HR) with associated 95% confidence intervals (CI). A total of 143 patients met the inclusion criteria. Their median age was 73 years, median Gleason score 8 and median abiraterone exposure 20 months. At the univariate analysis, a significant correlation with the duration of abiraterone exposure was found for Gleason score (HR 0.82, 95% CI 0.71-0.96; p=0.012), PSA (HR 1.10, 95% CI 1.03-1.18; p=0.08) and lactic dehydrogenase levels (HR 1.22, 95% CI 1.02-1.46; p=0.027), while the association between lower alkaline phosphatase levels and treatment duration was marginally significant (HR 1.07, 95% CI 0.99-1.16; p=0.074). Only PSA and Gleason score were predictive of long-term treatment duration in the multivariate analysis. No other clinical factors resulted to be predictive of sustained response to abiraterone, including metastatic disease at diagnosis and visceral disease, suggesting that all subgroups of patients may derive a substantial clinical benefit from abiraterone treatment. These findings need to be validated in prospective, larger studies.

AB - We aimed to identify clinical predictors of long-term response to abiraterone (defined as >12 months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 Italian centers. The Cox proportional hazards model was used to analyze the association between clinical features and the duration of drug exposure. Results were expressed as hazard ratios (HR) with associated 95% confidence intervals (CI). A total of 143 patients met the inclusion criteria. Their median age was 73 years, median Gleason score 8 and median abiraterone exposure 20 months. At the univariate analysis, a significant correlation with the duration of abiraterone exposure was found for Gleason score (HR 0.82, 95% CI 0.71-0.96; p=0.012), PSA (HR 1.10, 95% CI 1.03-1.18; p=0.08) and lactic dehydrogenase levels (HR 1.22, 95% CI 1.02-1.46; p=0.027), while the association between lower alkaline phosphatase levels and treatment duration was marginally significant (HR 1.07, 95% CI 0.99-1.16; p=0.074). Only PSA and Gleason score were predictive of long-term treatment duration in the multivariate analysis. No other clinical factors resulted to be predictive of sustained response to abiraterone, including metastatic disease at diagnosis and visceral disease, suggesting that all subgroups of patients may derive a substantial clinical benefit from abiraterone treatment. These findings need to be validated in prospective, larger studies.

KW - Abiraterone acetate

KW - Castration-resistant

KW - Predictive factors

KW - Prostate cancer

KW - Retrospective studies

UR - http://www.scopus.com/inward/record.url?scp=84982980466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982980466&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 40085

EP - 40094

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -